Get the Stockscreener App
3.17
0.63%
0.02
After Hours:
3.17
Absci Corp stock is traded at $3.17, with a volume of 2.80M.
It is up +0.63% in the last 24 hours and up +32.64% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
See More
Previous Close:
$3.15
Open:
$3.16
24h Volume:
2.80M
Relative Volume:
0.78
Market Cap:
$485.08M
Revenue:
$2.80M
Net Income/Loss:
$-115.18M
P/E Ratio:
-3.7413
EPS:
-0.8473
Net Cash Flow:
$-94.03M
1W Performance:
+6.02%
1M Performance:
+32.64%
6M Performance:
-36.60%
1Y Performance:
+1.60%
1-Day Range:
$3.08
$3.19
1-Week Range:
$2.86
$3.19
52-Week Range:
$2.24
$5.228
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.17 | 482.02M | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Redmile funds cut Absci (ABSI) holdings below 5% after share sale - Stock Titan
Portland InnoAbsci's move into generative AI | Why former Hydro Flask CEO joined Puffin - The Business Journals
Absci Corporation (NASDAQ:ABSI) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Absci Stock (ABSI) Opinions on Q4 Earnings and ABS-201 Trial Progress - Quiver Quantitative
ABSI Forecast, Price Target & Analyst Ratings | ABSCI CORP (NASDAQ:ABSI) - ChartMill
ABSI|Absci Corp|Price:2.990|Chg%:0.07 - TradingKey
Absci Corporation (ABSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference - Yahoo Finance
Absci: Compelling AI Biotech Story, but Weak Fundamentals and Bearish Structure - Investing.com
Highs Report: Can Absci Corporation lead its sector in growth2026 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Update Recap: Is Absci Corporation a top pick in the sectorWeekly Trade Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Is now the right time to enter Absci CorporationQuarterly Growth Report & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Targets Report: Will Absci Corporation benefit from government policy2026 Weekly Recap & Weekly High Potential Stock Alerts - baoquankhu1.vn
Insider Trends: Will Absci Corporation benefit from government policy2026 Breakouts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Absci Corp. Earnings Call: Betting on ABS-201 - TipRanks
Redmile Group (ABSI) reports 5.4% Absci stake as share count rises - Stock Titan
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Vanguard affiliates to report separately as ABSI holdings shift (ABSI) - Stock Titan
Here's Why We're Watching Absci's (NASDAQ:ABSI) Cash Burn Situation - finance.yahoo.com
What is HC Wainwright's Forecast for Absci FY2030 Earnings? - marketbeat.com
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $4.2 to $8 - 富途牛牛
Absci Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00 - GuruFocus
Absci Shares Fall on Wider 4Q Loss, Lower Revenue - news.futunn.com
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci’s AI-Native Integrated Drug Creation Platform: Advancing Antibody Therapeutics and Biopharma Innovation - Minichart
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
Absci reports Q4 EPS (20c), consensus (17c) - TipRanks
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions - Bitget
Absci Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips - Investing.com
Absci Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data - Stock Titan
Absci earnings missed by $0.02, revenue fell short of estimates - Investing.com
Absci (NASDAQ:ABSI) Announces Quarterly Earnings Results - MarketBeat
Absci shares slip nearly 4% on Q4 revenue miss, wider loss than expected - Investing.com
Absci 10-K: Partner revenue $2.8M, Net loss $115.2M, EPS $(0.84) - TradingView
ABSCI ($ABSI) Releases Q4 2025 Earnings - Quiver Quantitative
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):